You are here


22 - 02 - 2017

Stopping myocardial fibrosis

Myocardial fibrosis is a pathology that evolves towards congestive heart failure, a fatal disease. Caveolin-A plays an important role in cutaneous or pulmonary fibrosis. A replacement peptide called CSD, has blocked this profibrotic effect in animal models and human cells.

The study of a mouse model has shown that CSD also reduces myocardial fibrosis. Additional studies will be conducted to try and make CSD a new treatment for myocardial fibrosis and congestive heart failure.